Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Fosbretabulin

Generic Name: Fosbretabulin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁O_₈P

CAS Number: 222030-63-9

Unique Ingredient Identifier: I5590ES2QZ

Overview

Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Background

Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Phase 1

Terminated

Posted: 2017/01/09

Sponsor:

Lowell Anthony, MD

ID:NCT03014297

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Phase 2

Terminated

Posted: 2015/12/29

Sponsor:

Mateon Therapeutics

ID:NCT02641639

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Phase 2

Completed

Posted: 2014/10/31

Sponsor:

Mateon Therapeutics

ID:NCT02279602

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Phase 2

Completed

Posted: 2014/05/07

Sponsor:

Mateon Therapeutics

ID:NCT02132468

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Phase 1

Terminated

Posted: 2014/02/05

Sponsor:The Christie NHS Fou...

ID:NCT02055690

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy